Anti-inflammatory drug approved for use after cataract surgery

June 7, 2011

A non-steroidal anti-inflammatory drug (NSAID), for the treatment of postoperative ocular inflammation following cataract extraction, has been approved for use in the European market by the European Commission.

A non-steroidal anti-inflammatory drug (NSAID), for the treatment of postoperative ocular inflammation following cataract extraction, has been approved for use in the European market by the European Commission.

Yellox, owned by CROMA, is to be administered twice daily as an ocular NSAID in adult patients after undergoing cataract surgery. Otherwise known as, Yellox (bromfenac sodium) targets the COX-2 enzyme- one of the prime causes of prostaglandin production and ocular inflammation. The solution penetrates through the cornea and ocular tissues to treat ocular inflammation.

CROMA will collaborate with Bausch+Lomb to promote the ophthalmic solution in Austria, France, Spain, Poland and Romania. Bausch+Lomb will manage promotions in the remaining EU countries.

Chief Medical Officer of Bausch+Lomb, Dr Cal Roberts, said: “Yellox is very promising for cataract surgery patients. The drug helps meet the unmet needs of both patients and physicians alike across a number of European markets, offering them a new choice to treat post-operative ocular inflammation following cataract extraction.”